Introduction
Approximately 70% of invasive breast cancers at diagnosis are hormone receptorpositive and HER2-negative (HR+/HER2-) 1, 2 . However, HR+/HER2-disease is clinically and biologically heterogeneous and further subclassifications are needed to better tailor current and future treatments [3] [4] [5] .
Over the last decade, molecular characterization studies have identified and extensively investigated the two main molecular subtypes within HR+/HER2-disease (i.e.
Luminal A and B) 1, 2, 6 . Luminal A tumors have an improved prognosis at 5-and 10-year follow-up compared with Luminal B tumors irrespective of classical clinical-pathological variables (e.g. tumor size and nodal status) and (neo)adjuvant treatment (i.e. endocrine and chemotherapy) 1, 2, 7, 8 . In terms of treatment sensitivity, Luminal A tumors achieve significant lower rates of pathological complete response (pCR) than Luminal B tumors following neoadjuvant multi-agent chemotherapy [9] [10] [11] [12] . However, less clear is the difference in endocrine sensitivity between the two luminal subtypes 13, 14 .
Today, adjuvant endocrine therapy for 5-10 years is recommended for all patients with HR+/HER2-early breast cancer, whereas chemotherapy is recommended for patients with intermediate and high risk tumors 15 . However, the relationship between therapy and risk warrants further study considering that risk is associated with both factors related to tumor biology and clinical-pathological features such as tumor size and nodal status, whereas therapy responsiveness is generally considered to be independent of clinicalpathological factors. 
Methods and Materials

GEICAM/2006-03 clinical trial
Independent/testing datasets
Gene expression and response data were evaluated from 4 independent neoadjuvant datasets (Supplemental Material) 14, . Gene expression and survival data were evaluated from 4 independent datasets of patients with early breast cancer (Supplemental Material) 2, 20, 25, 26 .
Intrinsic subtype assignment
All tumors were assigned to an intrinsic molecular subtype of breast cancer (Luminal A, Luminal B, HER2-enriched, Basal-like) and the normal-like group using the research-based PAM50 subtype predictor 27, 28 , except for the Malaga cohort where the PAM50 standardized and commercial nCounter-based assay was used. Before subtyping, each individual dataset was normalized accordingly as previously reported
29
, except for the Malaga cohort that was normalized by Nanostring according to their algorithm. Of note, the Edinburgh microarray-based dataset is composed of ER+ samples-only and proper centering for intrinsic subtyping calling was not possible 30 . In this dataset, CES vas evaluated as a continuous variable since it is not affected by centering.
Combined cohort of primary breast cancer
To evaluate the relationship between PAM50 subtype calls, prognosis (ROR-P) and CES, we combined PAM50 data from 7 independent and previously reported cohorts 1, 2, 11, 20, [31] [32] [33] representing a total of 6,007 primary tumor samples. CES was evaluated in each individual cohort, and a combined matrix was created (Supplemental Material). Univariate and multivariable Cox-models were used to test the independent prognostic significance of each variable. Reported P values are two-sided.
Statistical analysis
Results
GEICAM 2006-03 dataset
Sixty-three pre-and post-menopausal patients were evaluated in this study ( We then evaluated the interaction between the expressions of each individual gene with response to therapy (endocrine vs. chemotherapy). Interestingly, 41 of the 70 genes associated with response to endocrine therapy, and 8 of 17 genes associated with chemotherapy response, showed a significant interaction with treatment (P<0.05 uncorrected for multiple comparisons). Thus, the biological factors associated with endocrine sensitivity seemed to be associated, at the same time, with chemotherapy resistance, and vice versa. Indeed, an overall inverse pattern was observed between expression of most genes and response to treatment (Fig. 1A) .
To further understand the biological factors associated with treatment response, we evaluated the mean expression of genes associated with high endocrine but low chemotherapy sensitivity, or low endocrine but high chemotherapy sensitivity, across 1,034 primary tumors representing all intrinsic molecular subtypes of breast cancer (Fig. 1B) . The results revealed that the biology associated with chemo-endocrine sensitivity is mostly driven by the Luminal A (i.e. high endocrine but low chemotherapy sensitive) vs. Basallike biology (i.e. low endocrine but high chemotherapy sensitive).
Development of a PAM50-based CES
Our previous results suggested that capturing the relative differences in the Luminal A vs. Basal-like biology within HR+/HER2-could help better predict endocrine and chemotherapy sensitivity. To capture this biological state in each tumor, we obtained, from the PAM50 classification algorithm, the correlation coefficients (CC) of each sample to the PAM50 Luminal A and Basal-like subtype centroids, and then subtracted the 2 values to create the Chemo-Endocrine Score (CES=CC to Luminal A -CC to Basal-like). Thus, samples with a positive score were identified as being more endocrine sensitive than chemotherapy sensitive, whereas samples with a negative score were identified as being more chemotherapy sensitive (CES-C) than endocrine sensitive (CES-E) ( 
MDACC-based dataset
We evaluated a combined dataset of 272 patients with HR+/HER2-disease treated with anthracycline/taxane-based neoadjuvant chemotherapy across several neoadjuvant trials ( Table 2) . In this dataset, 51.5%, 25.8% and 22.7% of the samples were identified as CES-E, -U and -C, respectively. The rates of pCR across the CES-E, -U and -C groups were 2.4%, 9.0% and 23.7%, respectively (P<0.0001), and were found to be similar even if non-luminal tumors were removed (2.2%, 8.8% and 25.0%). The neoadjuvant chemotherapy predictive ability of CES was independent of clinical-pathological variables and intrinsic subtype ( Table 3 and Table S1 ). Similar results were obtained when residual cancer burden was used as the endpoint (Tables S2-3) . 
Malaga-based dataset
We evaluated a dataset of 180 patients with HR+/HER2-disease treated with anthracycline/taxane-based neoadjuvant chemotherapy ( Table 2) . In this dataset, 46.1%, 16.1% and 37.8% of the samples were identified as CES-E, -U and -C, respectively. The pCR and RCB 0/1 rates across the CES-E, -U and -C groups were 2.4%/9.6%, 3.4%/17.2%
and 13.2%/30.9%, respectively (P=0.022 and 0.004).
To test the ability of CES to predict chemotherapy response independently of known clinical-pathological variables and intrinsic subtype, we performed a multivariable logistic regression analysis using RCB (0/1 vs. 2/3) as the endpoint since only 12 samples achieved a RCB 0 (i.e. pCR) in this dataset. The results revealed that CES provided independent predictive information beyond intrinsic subtype (Table 4) , Ki-67 by IHC (Table S13 ) and PAM50 ROR score ( Table S14 ). The aROC of CES for predicting RCB 0/1 was 0.746. Finally, we observed a significant association between CES and MillerPayne response data (Fig. S1) .
Marsden-based dataset: CES and endocrine sensitivity
We evaluated a dataset of 103 post-menopausal patients with HR+ disease treated with anastrozole for 16 weeks in the neoadjuvant setting ( Table 2) . In this dataset, 23.5%, 34.3% and 42.2% of samples were identified as CES-E, -U and -C, respectively. Clinical tumor response (complete and partial response versus stable and progressive disease) was used as the endpoint. No pCR was observed in this dataset. The rates of clinical tumor response across the CES-E, -U and -C groups were 75.0%, 48.6% and 44.2%, respectively (P=0.043). CES was found to be the only variable significantly associated with response (Table S15) , independently of HER2 status (Tables S15-16) .
Edinburgh-based dataset: CES and endocrine sensitivity
We evaluated a dataset of 120 post-menopausal patients with HR+ disease treated with letrozole for at least 12 weeks in the neoadjuvant setting (Fig. S2A) . Two patients of 120 achieved a complete response. Similar to previous results, CES as a continuous variable was found to be the only variable significantly associated with a ≥70% reduction in tumor volume by 90 days (Fig. S2B) , even within HER2-negative disease (Fig. S2C) .
Prognosis, intrinsic subtype and chemo-endocrine sensitivity
To better understand the relationship between prognosis, intrinsic biology and chemo-endocrine sensitivity, we pulled together PAM50 data from many different datasets for a total of 6,007 primary breast cancers representing all subtypes (Fig. 2) . The results revealed that in the ROR-low group, 94.9% of cases were identified as CES-E and 100%
were of the Luminal A subtype. In the ROR-high, 92.1% of the samples were identified as In patients with node-negative disease treated without adjuvant systemic therapy, CES (as a continuous variable or as group categories) was found significantly associated with distant relapse-free survival (Fig. 3A) . The hazard ratio between the CES-C group vs the CES-E group was 2.68 (0.163-0.858 95% confidence interval). Similar results were obtained in the dataset where patients were treated with adjuvant tamoxifen-only (Fig. 3B) .
However, CES (as a continuous variable or as group categories) was not found significantly associated with survival outcome in 2 independent cohorts of patients treated with (neo)adjuvant chemotherapy and endocrine therapy ( Fig. 3C and D) .
Discussion
Our results are the first to confirm, in a randomized setting, an inverse relationship of endocrine and chemotherapy sensitivity in ER+ breast cancer. Previous evidence has suggested an inverse relationship of proliferation-and ER-related biological processes regarding endocrine and chemotherapy sensitivity of ER+ breast cancer. For example, two independent studies showed an inverse correlation between a 200-gene ER reporter score, or between TAU expression, an ER-related gene, and endocrine sensitivity and chemosensitivity 38, 39 . In addition, high recurrence score measured by Oncotype DX (Genomic Health, Inc., Redwood, CA) predicted little or no benefit from adjuvant tamoxifen therapy in the NSABP-B14 trial, but at the same time also predicted substantial benefit from adjuvant CMF chemotherapy in the NSABP-B20 trial 40, 41 . These results fit with our results showing that virtually all patients with ROR-high disease are identified as CES-C; however, our data also highlights that within ROR-high/CES-C disease not all ER+/HER2-samples are luminal (i.e. Luminal A or B) since non-luminal disease (i.e.
Basal-like and HER2-enriched) can also be identified. According to our results (Fig. 2) , the chemotherapy benefit of ROR-high/non-luminal tumors within HR+/HER2-disease is likely even greater than ROR-high/Luminal B tumors.
Our results also suggest that a main driver of endocrine therapy sensitivity and chemotherapy sensitivity within ER+/HER2-disease is the Basal-like versus Luminal A intrinsic biology. To capture both biological states in each individual sample, we calculated the correlation coefficients of each sample to both PAM50-centroids (i.e. Luminal A and Basal-like) and then subtracted both coefficients. Thus, instead of choosing a gene signature (e.g. a proliferation-based signature) of the many signatures that can discriminate between both subtypes in one way or another, we decided to incorporate into a score the Basal-like vs. Luminal A intrinsic state of each tumor as identified by the PAM50 subtype predictor. Of note, the PAM50 genes were originally selected for their ability to capture the intrinsic biology displayed by 1,900 genes (i.e. the so-called intrinsic gene list). In fact, in the TCGA, intrinsic subtype defined by PAM50 captured the vast majority of the biological diversity displayed by most molecular data-types analyzed 1 .
From a clinical perspective, our results support current breast cancer guidelines for the systemic treatment of early HR+/HER2-breast cancer. On one hand, patients with a low-ROR score and a low tumor burden (i.e. <10% risk of distant relapse at 10 years) are recommended to be treated with endocrine therapy-only 42 . Indeed, our results suggest that these patients have tumors that are highly endocrine sensitive and have low chemotherapy sensitivity. On the other hand, patients with high-risk HR+/HER2-disease are recommended to be treated with endocrine therapy and chemotherapy. According to our analysis, this group is the one with high chemotherapy benefit and low endocrine benefit.
Regarding endocrine therapy in this group, the main issue is that we do not have survival data suggesting that CES-C tumors do not benefit at all from endocrine therapy. Therefore, withdrawal of a potentially efficacious treatment strategy such as endocrine therapy in a patient with an ER+ tumor (as defined by the ASCO/CAP guidelines) that is identified as CES-C or ROR-high should not be recommended today, although in patients whose tumors contain low levels of ER (1% to 10%), ASCO/CAP recommend to discuss the pros and cons of endocrine therapy. A large randomized adjuvant trial involving thousands of patients to answer this particular question is unlikely to happen. , have been specifically designed or trained to predict outcome and not intrinsic tumor biology or treatment sensitivity. Although a strong negative correlation is observed between ROR (risk) and CES (drug sensitivity), there are substantial differences between them at the individual level (40% discordance).
There are several caveats to our study. First, this is a retrospective study involving heterogeneous patient populations and the results need to be confirmed in a prospective clinical trial(s). Second, although the data presented here validates CES from a clinical perspective, further analytical validation will be needed since in most datasets, except the Malaga set, the research-based version of PAM50 was used. However, the fact that CES (as a continuous variable and the 2 cut-points) predicted pCR in the Malaga set suggests that analytical validation of this biomarker is feasible. Third, we did not evaluate the association of CES with survival data from a randomized clinical trial of adjuvant chemotherapy vs no adjuvant chemotherapy, or adjuvant endocrine therapy versus no adjuvant endocrine therapy. Thus, the predictive value of these signatures was only evaluated in the neoadjuvant setting where different tumor response endpoints were evaluated, most of which have been associated with patient survival 18, 44 . Fourth, some of the signatures evaluated in the MDACC-based dataset, such as OncotypeDX recurrence score or genomic grade index, were derived from microarray-based data and thus are not the commercially available versions. Fifth, we were not able to demonstrate a consistent association of CES with endocrine response in HR+ disease after excluding the HER2-positive cases. In the Edinburgh dataset, HER2 status was not available for all patients. Although we derived an ERBB2 expression-based surrogate definition of HER2 status and showed that CES is independently associated with response, this was not prespecified and does not meet REMARK guidelines. In addition, the association of CES with endocrine response did not reach statistical significance (p=0.09) in patients with HR+/HER2-negative disease in the Marsden dataset. Finally, patients from each of the datasets received different anthracycline/taxane-based chemotherapy regimens, schedules and doses, and thus the ability of the signatures to predict response to particular chemotherapeutics or treatment regimens could not be tested.
Another important consideration of our study is that we did not attempt to identify an optimal cutoff(s) for CES but rather focused on the association of the continuous expression of CES with each endpoint. The main reason is that different gene expressionbased platforms and protocols were used in each cohort and thus, standardization of a biomarker cut-point would have been difficult to achieve and most likely unreliable. In any case, the fact that all four testing sets gave very similar associations, and were found independently of the platform/protocol used, argues in favor of a robust finding. 
